(firstQuint)Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies.

 MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors.

 MGCD265 was shown to slow down the growth of human cancer cells in mice.

 Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients.

 In this study, MGCD265 is orally administered on a daily basis to patients with advanced malignancies.

.

 Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies@highlight

In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.

